Patents by Inventor Tianbao Lu

Tianbao Lu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20060241148
    Abstract: The present invention describes compounds of Formula I or a pharmaceutically acceptable salt thereof, for the prophylaxis, or treatment of diseases and conditions related to thrombin activity in a mammal. The present invention also relates to a novel method of N-oxidation of nitrogen containing heteroaryls.
    Type: Application
    Filed: March 21, 2006
    Publication date: October 26, 2006
    Inventors: Kevin Kreutter, Tianbao Lu, Yu Lee, Christopher Teleha, Mark Player, Xizhen Zhu
  • Publication number: 20060235007
    Abstract: The present invention is directed to novel 1,4-diazepines, pharmaceutical compositions thereof and the use thereof as inhibitors of HDM2-p53 interactions.
    Type: Application
    Filed: June 14, 2006
    Publication date: October 19, 2006
    Inventors: Tianbao Lu, Karen Milkiewicz, Pierre Raboisson, Maxwell Cummings, Raul Calvo, Daniel Parks, Louis LaFrance, Juan Marugan Sanchez, Joan Gushue, Kristi Leonard
  • Patent number: 7115598
    Abstract: The present invention is directed to novel 1,4-diazepines, pharmaceutical compositions thereof, and the use thereof as inhibitors of HDM2-p53 interactions.
    Type: Grant
    Filed: April 21, 2004
    Date of Patent: October 3, 2006
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Tianbao Lu, Karen L. Milkiewicz, Pierre Raboisson, Maxwell David Cummings, Raul R. Calvo, Daniel J. Parks, Louis V. Lafrance, III, Juan Jose Marugan Sanchez, Joan Gushue, Kristi Leonard
  • Publication number: 20060211719
    Abstract: Aminoguanidine and alkoxyguanidine compounds are described, including compounds of the Formula VII: wherein X is O or NR9 and Het, R1, R7, R8, R12-R15, Ra, Rb, Rc, Z, and n are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin. Also described are methods for preparing such compounds. The compounds of the invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin. The invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier.
    Type: Application
    Filed: October 19, 2005
    Publication date: September 21, 2006
    Applicant: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Tianbao Lu, Bruce Tomczuk, Thomas Markotan, Colleen Siedem
  • Publication number: 20060199809
    Abstract: The present invention is directed to novel compounds of Formula I: and forms and pharmaceutical compositions thereof, and the use thereof as inhibitors of Factor Xa.
    Type: Application
    Filed: October 24, 2005
    Publication date: September 7, 2006
    Inventors: Tianbao Lu, Tho Thieu, Yu-Kai Lee, Daniel Parks, Thomas Markotan, Wenxi Pan, Karen Milkiewicz, Mark Player
  • Publication number: 20060189511
    Abstract: The present invention is directed to a method of protecting one or more cells from programmed cytotoxic cell death by contacting the cells with a cytoprotective amount of an MDM2 and/or HDM2 inhibitor. The cytoprotective amount of inhibitor is typically used as a pulsed administration. Useful inhibitors include a class of 1,4-benzodiazepines, which act as inhibitors of MDM2-p53 interactions. The method of the invention can be employed as an adjunct to chemotherapy or radiation therapy. In addition, the methods of the invention can be employed to treat a disease or condition that involves excessive cell death.
    Type: Application
    Filed: May 13, 2003
    Publication date: August 24, 2006
    Inventors: Holly Koblish, Carl Manthey, Christopher Molly, Tianbao Lu, Daniel Parks, Louis Lafrance, Karen Milkiewicz, Theodore Carver, Bruce Grasberger
  • Publication number: 20060148792
    Abstract: The present invention is directed to novel 1,4-benzodiazepines, pharmaceutical compositions thereof, and the use thereof as inhibitors of HDM2-p53 interactions.
    Type: Application
    Filed: March 9, 2006
    Publication date: July 6, 2006
    Inventors: Tianbao Lu, Louis LaFrance, Daniel Parks, Karen Milkiewicz, Raul Calvo, Maxwell Cummings, Alexander Kim, Bruce Grasberger, Theodore Carver
  • Patent number: 7067512
    Abstract: The present invention is directed to novel 1,4-benzodiazepines, pharmaceutical compositions thereof, and the use thereof as inhibitors of HDM2-p53 interactions.
    Type: Grant
    Filed: November 13, 2002
    Date of Patent: June 27, 2006
    Inventors: Tianbao Lu, Louis V Lafrance, III, Daniel J Parks, Karen L Milkiewicz, Raul R Calvo, Maxwell D Cummings, Alexander J Kim, Bruce L Grasberger, Theodore E Carver, Jr.
  • Patent number: 7029654
    Abstract: Aminoguanidine and alkoxyguanidine compounds are described, including compounds of the Formula VII: wherein X is O or NR9 and Het, R1, R7, R8, R12—R15, Ra, Rb, Rc, Z, and n are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin. Also described are methods for preparing such compounds. The compounds of the invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin. The invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: November 17, 2003
    Date of Patent: April 18, 2006
    Assignee: Ortho-McNeil Pharmaceuticals, Inc.
    Inventors: Tianbao Lu, Bruce E. Tomczuk, Thomas P. Markotan, Colleen Siedem
  • Patent number: 7030110
    Abstract: Cyclic oxyguanidine pyrazinone compounds are described, including compounds of the Formula I: wherein R3, R4, R5, W, and A are as set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof. The compounds of the invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin. Compositions for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation are described.
    Type: Grant
    Filed: October 4, 2002
    Date of Patent: April 18, 2006
    Assignee: Ortho-McNeil Pharmaceuticals, Inc.
    Inventors: Aihua Wang, Bruce Edward Tomczuk, Tianbao Lu, Richard M. Soll, John Curtis Spurlino, Roger Francis Bone
  • Publication number: 20060058291
    Abstract: Cyclic oxyguanidine pyrazinone compounds are described, including compounds of the Formula I: wherein R3, R4, R5, W, and A are as set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof. The compounds of the invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin. Compositions for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation are described.
    Type: Application
    Filed: October 19, 2005
    Publication date: March 16, 2006
    Applicant: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Aihua Wang, Bruce Tomczuk, Tianbao Lu, Richard Soll, John Spurlino, Roger Bone
  • Publication number: 20050227932
    Abstract: The present invention is directed to a combinational therapy for treating cancer or other cell proliferative diseases. Such a therapy combines the use of radiation therapy or chemotherapy with the use of a small molecule inhibitor of the MDM2: p53 interaction.
    Type: Application
    Filed: March 4, 2005
    Publication date: October 13, 2005
    Inventors: Tianbao Lu, Holly Koblish, Anna Maroney
  • Publication number: 20050209225
    Abstract: The present invention relates to novel substituted indole compounds that are antagonists of alpha V (?v) integrins, for example ?v?3 and ?v?5 integrins, their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. The compounds may be used in the treatment of pathological conditions mediated by ?v?3 and ?v?5 integrins, including such conditions as tumor growth, metastasis, restenosis, osteoporosis, inflammation, macular degeneration, diabetic retinopathy, and rheumatoid arthritis. The compounds have the general formula: where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, D, X, W, a, m, n, i, j, k and v are defined herein.
    Type: Application
    Filed: December 6, 2004
    Publication date: September 22, 2005
    Inventors: Tianbao Lu, Louis LaFrance, Bruce Tomczuk, Thomas Markotan, Juan Marugan Sanchez, Victor Marder, David U'Prichard, Beth Anaclerio, Zihong Guo, Wenzi Pan, Kristi Leonard
  • Publication number: 20050159457
    Abstract: Phenyl acetamide compounds are described, including compounds of Formula I: or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R3-R6, R11, B, Y and W are set forth in the specification. The compounds of the invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as thrombin and factor Xa. Compositions for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation are described. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents. Additionally, the compounds can be detectably labeled and employed for in vivo imaging of thrombi.
    Type: Application
    Filed: January 10, 2005
    Publication date: July 21, 2005
    Inventors: Wenxi Pan, Tianbao Lu, Thomas Markotan, Bruce Tomczuk
  • Patent number: 6900231
    Abstract: Phenyl acetamide compounds are described, including compounds of or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R3-R6, R11, B, Y and W are set forth in the specification. The compounds of the invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as thrombin and factor Xa. Compositions for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation are described. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents. Additionally, the compounds can be detectably labeled and employed for in vivo imaging of thrombi.
    Type: Grant
    Filed: October 3, 2002
    Date of Patent: May 31, 2005
    Assignee: 3-Dimensional Pharmaceuticals, Inc.
    Inventors: Wenxi Pan, Tianbao Lu, Thomas P. Markotan, Bruce E. Tomczuk
  • Publication number: 20050100503
    Abstract: A method of decomposing gypsum to sulfur dioxide, and the apparatus thereof are disclosed. The apparatus comprises a set of four-stage cyclone preheater and a rotary kiln for decomposing and calcining. In the four-stage cyclone preheater, the off-gas of the kiln conducts heat-exchange with materials. By such processing, the efficiency of heat exchange is high, and gypsum which contains 10-25% of water can be directly used for preparing crude materials. The entrance temperature of the preheated materials can be up to 600-720° C., while the temperature of the off-gas can be decreased to 260-400° C., so that heat utilization ratio is high, and the cost of the apparatus can be cut down. The concentration of SO2 in the off-gas may be up to 11-14%, so that two-conversion two-adsorption process can be employed for preparing sulfuric acid.
    Type: Application
    Filed: May 18, 2001
    Publication date: May 12, 2005
    Inventors: Yisheng Feng, Jiutian Feng, Xigang Liu, Yurui Wang, Tianbao Lu
  • Publication number: 20040254166
    Abstract: Phenyl acetamide compounds are described, including compounds of Formula I: 1
    Type: Application
    Filed: April 1, 2004
    Publication date: December 16, 2004
    Inventors: Kevin D. Kreutter, Lily Lee, Tianbao Lu, Venkatraman Mohan, Sharmila Patel, Hui Huang, Guozhang Xu, Mark Fitzgerald
  • Publication number: 20040220179
    Abstract: The present invention is directed to novel 1,4-diazepines, pharmaceutical compositions thereof, and the use thereof as inhibitors of HDM2-p53 interactions.
    Type: Application
    Filed: April 21, 2004
    Publication date: November 4, 2004
    Inventors: Tianbao Lu, Karen L. Milkiewicz, Pierre Raboisson, Maxwell David Cummings, Raul R. Calvo, Daniel J. Parks, Louis V. Lafrance, Juan Jose Marugan Sanchez, Joan Gushue, Kristi Leonard
  • Publication number: 20040106633
    Abstract: Aminoguanidine and alkoxyguanidine compounds are described, including compounds of the Formula VII: 1
    Type: Application
    Filed: November 17, 2003
    Publication date: June 3, 2004
    Applicant: 3-Dimensional Pharmaceuticals, Inc.
    Inventors: Tianbao Lu, Bruce E. Tomczuk, Thomas P. Markotan, Colleen Siedem
  • Patent number: 6730783
    Abstract: Aminoguanidine and alkoxyguanidine compounds, including compounds of the formula: wherein X is O or NR9 and R1-R4, R6-R9, R11, R12, Ra, Rb, Rc, Y, Z, n and m are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin are described. Also described are methods for preparing the compounds of Formula I. The novel compounds of the present invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin, or are intermediates useful for forming compounds having antithrombotic activity.
    Type: Grant
    Filed: April 22, 2003
    Date of Patent: May 4, 2004
    Assignee: 3-Dimensional Pharmaceuticals, Inc.
    Inventors: Bruce E. Tomczuk, Richard M. Soll, Tianbao Lu, Cynthia L. Fedde, Carl R. Illig, Thomas P. Markotan